文献速递皮肤肿瘤

一氧化氮释放型选择性雌激素受体调节剂在恶性黑色素瘤中的治疗潜力

Therapeutic Potential of Nitric Oxide‒Releasing Selective Estrogen Receptor Modulators in Malignant Melanoma.
PubMed 文献 · J Invest Dermatol · 2022-01-03

研究回顾性分析448例黑色素瘤患者的雌激素受体基因表达,发现ERα基因(ESR1)高表达与总生存改善相关(HR=0.881,95%CI 0.793-0.979,P=0.018)且随肿瘤分期增加,而ERβ基因(ESR2)表达不随肿瘤进展变化。基于此,作者探讨ERβ选择性调节剂NO-SERM 4d对黑色素瘤细胞系的作用,发现其显著降低A2058和MEL-JUSO细胞的促转移行为,减少N-钙黏蛋白表达并损害A2058细胞球形成,显著减少A2058细胞球生长。

要点

  • ERα基因(ESR1)高表达与黑色素瘤患者总生存改善相关(HR=0.881,95%CI 0.793-0.979,P=0.018)。
  • ERβ基因(ESR2)表达不随肿瘤进展变化。
  • NO-SERM 4d显著降低A2058和MEL-JUSO细胞的促转移行为。

核心结论

  • 靶向ERβ信号联合靶向一氧化氮释放是恶性黑色素瘤中有前景的治疗方法,可能预防转移扩散并减少肿瘤生长。

研究设计与样本

  • 回顾性分析448例黑色素瘤患者的ER基因表达谱,并在A2058和MEL-JUSO两种黑色素瘤细胞系中研究NO-SERM 4d的作用。

主要发现

  • ERα基因(ESR1)高表达与总生存改善相关(HR=0.881,95%CI 0.793-0.979,P=0.018),且随肿瘤分期增加。
  • ERβ基因(ESR2)表达不随肿瘤进展变化。
  • NO-SERM 4d显著降低A2058和MEL-JUSO两种黑色素瘤细胞系的促转移行为。
  • NO-SERM 4d减少A2058细胞N-钙黏蛋白表达并损害细胞球形成。
  • NO-SERM 4d显著减少A2058细胞球生长,证实其抗肿瘤潜力。

关键数值与推荐

  • ERα基因(ESR1)高表达与总生存改善相关:HR=0.881,95%CI 0.793-0.979,P=0.018。
  • ERβ基因(ESR2)表达不随肿瘤进展变化。
  • NO-SERM 4d显著降低A2058和MEL-JUSO细胞的促转移行为。
  • NO-SERM 4d减少A2058细胞N-钙黏蛋白表达并损害细胞球形成。
  • NO-SERM 4d显著减少A2058细胞球生长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant melanoma has a steadily increasing incidence, but treatment options are still limited, and the prognosis for patients, especially for men, is poor. To investigate whether targeting estrogen receptor (ER) signaling is a valid therapeutic approach, we retrospectively analyzed ER gene expression profiles in 448 patients with melanoma. High ERα gene (ESR1) expression was associated with improved overall survival (hazard ratio = 0.881; 95% confidence interval = 0.793-0.979; P = 0.018) and increased with tumor stage, whereas ERβ gene (ESR2) expression did not change with tumor progression. This seemingly protective function of ERα led us to speculate that specific targeting of ERβ has a therapeutic benefit in malignant melanoma. An ERβ-selective ER modulator with nitric oxide‒releasing moiety (nitric oxide‒releasing selective ER modulator 4d [NO-SERM 4d]) significantly reduced the prometastatic behavior of two melanoma cell lines (A2058 and MEL-JUSO). Epithelial‒mesenchymal transition in melanoma is consistent with a switch from E- to N-cadherin expression, mediating the invasive phenotype. NO-SERM 4d reduced N-cadherin expression and impaired spheroid formation in A2058 cells. In addition, the growth of A2058 spheroids was significantly reduced, confirming the antitumorigenic potential of NO-SERM 4d. Targeting ERβ signaling combined with targeted nitric oxide release represents a promising therapeutic approach in malignant melanoma that has the potential to prevent metastatic spread and reduce tumor growth.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Bechmann N, Calsina B, Richter S, et al. Therapeutic Potential of Nitric Oxide‒Releasing Selective Estrogen Receptor Modulators in Malignant Melanoma. J Invest Dermatol. 2022. PMID: 34990694. doi:10.1016/j.jid.2021.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。